Condition

Sjogrens Disease

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 2 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting1

Common interventions2

Lead sponsors shown2

Clinical trials

2 shown

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.NCT06991114 · 2025-07-09

RECRUITING

Quest to Analyze One Thousand Humans MeditatingNCT06583395 · 2021-12-05

ENROLLING_BY_INVITATION

Common interventions

Advanced multi-component meditation practiceBEHAVIORAL1 Allogeneic NK CellsDRUG1

Leading sponsors

Artiva Biotherapeutics, Inc. 1 Tobias Moeller-Bertram 1

Trial status mix

ENROLLING_BY_INVITATION1

RECRUITING1

Phase mix

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.